Kymera Therapeutics, Inc.

Kymera Therapeutics, (www.kymeratx.com) Inc. is a biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. Its targeted protein degradation platform, Pegasus, allows it to discover selective small molecule protein degraders with activity against disease-causing proteins throughout the body. Its Pegasus platform, includes E3 Ligase Whole-Body Atlas, E3 Ligase Binders Toolbox, Ternary Complex Modeling, Quantitative System Pharmacology Model and Proprietary Chemistry. Its therapeutic pipeline programs includes IRAK4, IRAKIMiD, and STAT3, which each focus on a single critical signaling node within the genetically and clinically validated interleukin-1 receptor/toll-like receptor ( IL-1R/TLR) and janus kinase/signal transducers and activators of transcription (JAK/STAT) pathways.

• Kymera Therapeutics, Inc.